FDA approves brand name for Actelion's PAH drug as Veletri; PAH registry now enrolling patients

26 August 2010

The US subsidiary of Switzerland-based Actelion, Europe's largest biotechnology firm, says that the US Food and Drug Administration has approved the brand name Veletri for the company's epoprostenol for injection therapy.

The drug has been commercially available since April this year as Epoprostenol for Injection for the treatment of moderate to severe pulmonary arterial hypertension and PAH associated with the scleroderma spectrum of disease. Actelion plans to release Veletri-labeled product by early fourth quarter of 2010.

Veletri is an improved formulation of epoprostenol that offers greater convenience to patients than other epoprostenol formulations. It is stable at room temperature for up to 24 hours when diluted as directed and put into the pump for administration, eliminating the need for ice packs, the company notes.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology